Skip to content

Clinical Investigation on the Effects of a Vegetable Juice Treatment

The Use of a Commercial Vegetable Juice as a Practical Means to Increase Vegetable Intake: A Randomized Controlled Trial

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01161706
Enrollment
90
Registered
2010-07-13
Start date
2007-07-31
Completion date
2009-02-28
Last updated
2010-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Pressure, Cardiovascular Disease, Vegetables

Keywords

vegetable juice, cardiovascular, blood pressure

Brief summary

The purpose of the investigators study is to investigate the impact of a commercial vegetable juice on dietary vegetable intake and select cardiovascular risk factors in a generally healthy population. The study was a 12 week study with 3 groups who received 0, 8 or 16 fluid ounces daily of vegetable juice, along with education on the DASH (Dietary Approaches to Stop Hypertension) diet. All participants came in for 3 study visits at 0, 6 and 12 weeks into the study.

Interventions

Participants consumed vegetable juice daily in the amount of 0, 8 or 16 fluid ounces.

Sponsors

University of California, Davis
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

\*\*\*Inclusion Criteria\*\*\* * Age 40 to 65 yrs * Subject's body mass index is between 18.5 - 34.9 kg/m2 * Subject is willing and able to comply with the study protocols * Subject is willing to consume a vegetable-based beverage daily for three months \*\*\*

Exclusion criteria

\*\*\* * Physical signs of health impairment * Uncontrolled diabetes or hypertension * Pregnant or lactating * Active tuberculosis or lung disease (i.e. COPD) * Renal or Liver disease * Heart Disease, which includes Cardiovascular events and Stroke * Cushing's syndrome * Exercise trained individuals * History of psychiatric disorders i.e. schizophrenia or bi-polar or depression treated with antidepressants within the last 1 year * Anxiety medications * Use of MAOI inhibitors within the last 1 year (e.g., phenelzine (Nardil), tranylcypromine (Parnate), etc.) * Quality of life score of 21 or above * Routine use of prescription drugs or over-the counter medications, which may potentially modulate the outcome of this study; including antibiotics, aspirin and aspirin-containing formulations, COX-2 inhibitors, antihistamines, corticosteroids, erectile dysfunction drugs * Asthma (can be worsened by mild to moderate food allergies) * Indications of substance or alcohol abuse within the last 3 years * The volunteer is undergoing nicotine cessation therapy * Laboratory values outside the reference range if determined to be clinically significant by Dr. M. Eric Gershwin * Individuals with known salt-sensitive hypertension * History of stage 1 high blood pressure defined as systolic \> 140 and diastolic \> 90, with or without use of HTN medications * Multi-Vitamin use other than a One-A-Day essential * Use of herbal or plant-based supplements; omega-3 fatty acids, and fish oils and unwilling to discontinue use while participating in the study * Allergies to vegetables

Design outcomes

Primary

MeasureTime frame
Dietary Vegetable Intake6 and 12 weeks
Dietary Nutrient Intake (vitamins & minerals)6 and 12 weeks

Secondary

MeasureTime frame
Selected Cardiovascular Risk Factors (lipids, blood pressure, TBARS/oxidative stress)0, 6 and 12 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 30, 2026